BACKGROUND A limitation of aspirin is that some patients, particularly those with diabetes, may not have an optimal antiplatelet effect.
F or several years, aspirin "resistance" has been a controversial topic.
Certainly, there are patients who are taking aspirin for cardiovascular protection who nevertheless experience a plateletmediated ischemic event. In some proportion of those cases, it may indeed be considered a clinical failure of aspirin, whereas in other cases, alternative pathological mechanisms may have been at play (1) . Some patients who do not seem to benefit from aspirin do not adhere to the recommended aspirin regimen for a variety of reasons, including gastric intolerance or bleeding (2, 3) . Pharmacological failure of aspirin, in which inadequate inhibition of its drug target, platelet cyclooxygenase (COX)-1, is documented by thromboxane (TX) measurement, seems to be infrequent (<6%) (4) .Suppression of TX is believed to explain aspirin's cardioprotective benefit mechanistically (5) .
Both aspirin dosing and enteric coating have been suggested to influence the antiplatelet effects of aspirin. No convincing clinical trial evidence exists that the dose level or scheduling of aspirin affects clinical outcomes in the chronic cardiovascular setting, although some data suggest that patients with diabetes mellitus may display less aspirin resistance with higher doses (i.e., 325 mg vs. 81 mg) or more frequent dosing intervals (twice daily vs. once daily) (6) (7) (8) (9) . The clinical effect of enteric-coated (EC) aspirin versus uncoated ("plain") aspirin on cardiovascular events has never been fully studied. Some data suggest greater variability of antiplatelet response to EC aspirin (10) (11) (12) . A study of healthy volunteers found that all detected aspirin nonresponsiveness was attributable to the enteric coating, presumably due to lower formulation-dependent bioavailability (12) .
In addition, aspirin is known to cause gastrointestinal discomfort and bleeding. However, it is not clear that the enteric coating actually reduces clinically significant gastrointestinal events, such as bleeding or ulceration (13) . A lipid-based formulation of aspirin (PL2200) has been shown in a randomized trial to reduce the risk of acute endoscopic ulceration compared with plain aspirin (14) . (17) (18) (19) .B r i e fly, immediately after approximately 4 ml of blood was drawn, the nonanticoagulated blood specimen was incubated for 1 h at 37 C, the resulting serum was isolated, and it was stored frozen until analysis. TXB 2 was quantified by using a validated high-performance liquid chromatography-tandem mass spectrometry assay (MEDTOX Scientific, St. Paul, Minnesota). The lower limit of quantitation of the method was 1.00 ng/ml using d 4 -TXB 2 as the internal standard. Abbreviations as in Figure 1 .
Bhatt et al. Their baseline characteristics are listed in Whiskers below and above the box are defined by 1.5 times the interquartile range. Observations outside the whiskers are considered as outliers. Abbreviations as in Figure 1 . formation over baseline (20, 21) . These are patients who may be considered intrinsically aspirin resistant.
Extent of inhibition of ex vivo platelet function.
The functional impact of the differences in COX-1 inhibition, as evidenced by the differences in serum TXB 2 with the 3 aspirin formulations, was reaffirmed by using platelet light transmittance aggregometry ex vivo. As expected, the kinetics of TXB 2 depletion and nonresponsiveness seemed to be consistent with AA-induced platelet aggregation (Figure 3) . Unlike plain aspirin and PL2200, EC aspirin maximum inhibition of AA-induced aggregation was observed after multiple doses. However, the collagen response was more variable (data not shown).
Aspirin nonresponsiveness may be due to poor aspirin absorption. We directly measured the plasma concentrations of aspirin at the same time as serum TXB 2 and platelet aggregation after the initial doses of the study drugs. The functional response was consistent with the single-dose bioavailability of ASA.
C max and AUC 0-t were significantly lower, and the time to reach C max was significantly higher, with EC aspirin compared with either plain aspirin or PL2200 ( Table 2 , Figure 4A ). The C max and AUC 0-t values for PL2200 were approximately 2.3-and 4.5-fold higher than those for EC aspirin (p < 0.0001) but similar to those for plain aspirin. Regression analysis indicated that the lower rate and extent of absorption for EC aspirin were consistent with a lower extent of COX-1 inhibition with marked intraindividual variability (data not shown).
If the high rate of incomplete responsiveness on the basis of TXB 2 is indeed mediated by a lower extent of absorption, the ASA C max for EC aspirin-treated responders should be greater than that for nonresponders. Therefore, in a post hoc analysis, each patient was classified as an EC aspirin responder or nonresponder on the basis of the single-dose response criterion of $99% depletion of TXB 2 .A m o n gt h eE C aspirin group, incomplete responders, as assessed by using TXB 2 levels, had significantly lower C max and more often had an ASA concentration <150 ng/ml at all time points (Table 3, Figure 4B ). These findings suggest that an incomplete response to EC aspirin is mediated by reduced absorption of ASA. mixed effects models in all the PD and PK analyses were >0.4, indicating that the washout interval was e f f e c t i v ea n dt h eo r d e ro fs t u d yd r u gt r e a t m e n t sh a d no effect.
Multivariable analysis. In a post hoc multivariable analysis, female sex was a significant independent predictor of nonresponsiveness to EC aspirin (p ¼ 0.0414).
Age, race, body mass index, duration of diabetes, or glycemic control were not independent predictors.
DISCUSSION
The results of this PK/PD trial show that there is substantial variability in antiplatelet response to Values are mean AE SD (N) or % (n/N). *The p values were assessed by using the 2-sample Student t test for continuous variables and the chi-square test for categorical variables. The plasma 150-ng/ml ASA cutoff is on the basis of plasma values 3 times the lower limit of quantitation of the method. Nonresponders were defined as those with #99% inhibition of thromboxane B2.
ASA ¼ acetylsalicylic acid; other abbreviations as in Table 2 .
Bhatt et al. Aspirin Nonresponsiveness in Type 2 Diabetes Mellitus FEBRUARY 14, 2017:603-12 In addition, because 325 mg of aspirin was used in each arm of the present study, it is unknown what w o u l dh a v eh a p p e n e dw i t ha s p i r i n8 1m g .H o w e v e r ,
given that variability with EC aspirin was high with 325 mg, it might be even higher with lower aspirin doses, as observed in previous research with 81 mg of daily EC aspirin, and the time required to achieve a therapeutic level of inhibition would likely be much longer (24) . Importantly, aspirin resistance remains difficult to define unequivocally, and our study design cannot provide data on cardiovascular outcomes or other potential clinical implications associated with aspirin use in patients with diabetes (25) . 
